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Title: 
Is there scope to discontinue non-essential medication in patients with advanced lung cancer? 
 
Abstract:  (Please refer to instructions to authors and example abstract) 
Focal Points 
1. Patients with advanced lung cancer take many ‘non-essential’ medicines  
2. A simple audit tool could be used to identify ‘non-essential’ medicines that could be discontinued  
3. Pharmacists have a potential role in identifying and reviewing ‘non-essential’ medicines 
 
Background 
Lung cancer patients can present with complex medical histories often taking medications to manage existing conditions 
and prevent future morbidity e.g. antihypertensives and antiplatelets.  Guidelines for discontinuing these medications in 
life-limiting illnesses, such as advanced lung cancer, have not been produced despite the potential to reduce burden, in 
terms of cost and, more importantly, discomfort to the patient.
1
 The objectives of this work was to audit the number of 
medications in patients taking erlotinib for the treatment of advanced lung cancer; and, develop a draft tool that can be 
used to identify non-essential medications which could, potentially, be discontinued. 
 
Methods 
This clinical audit was undertaken at an acute NHS Trust in April 2011.  A clinical audit tool was used to extract data 
from medical notes of patients receiving erlotinib for non-small cell lung cancer (NSCLC) and compared to a set of 
criteria to establish if the medicine is essential, non-essential or uncertain.  These criteria were based on a study that 
defined unnecessary medication as where there is no anticipated short-term benefit to patients with respect to survival, 
quality of life or symptom control.
2 
All patients who had received erlotinib in the Trust for the treatment of NSCLC 
within 18 months were selected for the audit.  A consensus group (consultant pharmacist, lung nurse specialist and 
consultant oncologist) reviewed results and considered which medications they would have stopped.   
 
Results  
Of the 20 patients audited, 19 were taking at least one medication that could have been discontinued.  The mean number 
of medications taken was 8 (range 1–16).  Seventeen patients were taking essential medications (e.g. analgesics) 
necessary for symptom control in cancer.  Non-essential medicines were regarded as those which provided no short term 
benefit to the patients with respect to survival, quality of life or symptom control or any medicine which had potential to 
cause harm.  The focus group concurred that the majority of non-essential medications identified by the criteria could 
have been discontinued.  Medications classified as uncertain were taken by 7 patients.  These medications need to be 
further reviewed.  
 
Discussion 
For patients undergoing treatment for terminal lung cancer the issue of discontinuing medications is not an immediate 
priority. However, at some point in their treatment pathway a discussion regarding their medications should be instigated.  
The focus group revealed that timing of this discussion is crucial.  The futile use of medication in terminally ill cancer 
patients has been reported in the literature and this work is in agreement with this by showing that patients with NSCLC 
taking erlotinib are taking unnecessary medications.
2   
 Patients take medications such as statins and antihypertensives 
with the belief that they will be taking them for the rest of their lives, therefore if an appropriate explanation for 
discontinuation is not given the patients and/or their families may misconceive this as a death-hastening intervention.  
This work also showed that a significant number of patients who are taking erlotinib also take a proton pump inhibitor 
(PPI) despite the fact there is a clinically significant drug interaction between erlotinib and PPIs where the absorption of 
erlotinib is reduced.
3
  In conclusion, patients taking erlotinib for the treatment of advanced NSCLC take many 
unnecessary medications and written guidelines on what can be withdrawn are needed. There is the potential for 
pharmacists to become involved in the review of patients with terminal cancer to facilitate discontinuing potentially 
unnecessary medicines. 
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